Literature DB >> 17149788

First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia.

K Spencer1, N J Cowans, I Chefetz, J Tal, H Meiri.   

Abstract

OBJECTIVE: To evaluate whether measurement of maternal serum placental protein-13 (PP-13) and pregnancy-associated plasma protein-A (PAPP-A) at 11 + 0 to 13 + 6 weeks of gestation alone or in combination with second-trimester uterine artery pulsitility measured by Doppler velocimetry is useful in predicting those women who will develop pre-eclampsia
METHODS: This was a nested case-control study of pre-eclampsia cases with controls matched for gestational age and storage time for the maternal serum. Samples were collected as part of a first-trimester prenatal chromosomal anomaly screening program and were routinely tested for PAPP-A. PP-13 was tested using an enzyme linked immunosorbent assay (ELISA) by an examiner who was blinded to pregnancy outcome. All patients also underwent uterine artery Doppler flow velocimetry to measure the mean pulsatility index (PI) at 22-24 weeks' gestation.
RESULTS: There were 446 controls and 44 cases with early pre-eclampsia where delivery was induced prior to 35 weeks. In addition there were a further 44 cases with pre-eclampsia in which delivery was not induced before term. Median PP-13 levels for controls, all cases and early pre-eclampsia cases were 176.9, 121.9 and 111.7 pg/mL, with multiples of the median (MoMs) of 1.00, 0.69 and 0.63, respectively (P < 0.001). PAPP-A MoMs were 1.00, 0.89 (P = 0.076) and 0.89 (P = 0.042) and mean PIs were 1.0, 1.6 (P < 0.001) and 1.7 (P < 0.001) for controls, all cases and early cases, respectively. Receiver-operating characteristics (ROC) curve analysis for either all cases or early cases vs. controls yielded areas under the curve for PP-13, PAPP-A and PI respectively of 0.68 (95% CI, 0.61-0.74; P < 0.001), 0.56 (95% CI, 0.49-0.63; P = 0.076) and 0.79 (95% CI, 0.72-0.87; P < 0.001) for all cases and 0.71 (95% CI, 0.63-0.79; P < 0.001), 0.59 (95% CI, 0.51-0.68; P = 0.076) and 0.86 (95% CI, 0.77-0.94; P < 0.001) for early cases. At a specificity set to 0.80 the sensitivities were 0.50, 0.23 and 0.76 for PP-13, PAPP-A and PI in the early cases and 0.44, 0.24 and 0.73 in all cases. Combining PP-13 and PI using logistic regression analysis yielded an area under the curve of 0.84 (95% CI, 0.78-0.90; P < 0.001) and a sensitivity of 0.74 in all cases, and 0.90 (95% CI, 0.84-0.96; P < 0.001) and a sensitivity of 0.79 for early cases. PAPP-A with PI gave an area under the curve of 0.82 (95% CI, 0.76-0.90; P < 0.001) and a sensitivity of 0.76 in all cases. Combining PAPP-A with PP-13 and PI did not add significantly to the sensitivity.
CONCLUSION: First-trimester PP-13 levels may be useful in predicting pre-eclampsia and early pre-eclampsia, and the accuracy of the method increases when coupled with second-trimester Doppler PI measurement. First-trimester PAPP-A provides some prediction for pre-eclamspia when combined with PI but does not add to the prediction of early pre-eclampsia when PP-13 and PI are used together. Further studies are required to establish the real value of PP-13 in first-trimester screening for pre-eclampsia. Copyright 2006 ISUOG. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17149788     DOI: 10.1002/uog.3876

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  42 in total

1.  How useful is uterine artery Doppler ultrasonography in predicting pre-eclampsia and intrauterine growth restriction?

Authors:  Lynne McLeod
Journal:  CMAJ       Date:  2008-03-11       Impact factor: 8.262

2.  Variation of papp-a level in the first trimester of pregnancy and its clinical outcome.

Authors:  Mithil Patil; T M Panchanadikar; Girija Wagh
Journal:  J Obstet Gynaecol India       Date:  2013-12-01

3.  First-trimester placental ultrasound and maternal serum markers as predictors of small-for-gestational-age infants.

Authors:  Nadav Schwartz; Mary D Sammel; Rita Leite; Samuel Parry
Journal:  Am J Obstet Gynecol       Date:  2014-03-05       Impact factor: 8.661

4.  Biochemical markers for prediction of preclampsia: review of the literature.

Authors:  Santo Monte
Journal:  J Prenat Med       Date:  2011-07

Review 5.  Galectins: guardians of eutherian pregnancy at the maternal-fetal interface.

Authors:  Nandor Gabor Than; Roberto Romero; Chong Jai Kim; Michael R McGowen; Zoltan Papp; Derek E Wildman
Journal:  Trends Endocrinol Metab       Date:  2011-10-27       Impact factor: 12.015

6.  The two stage model of preeclampsia: variations on the theme.

Authors:  J M Roberts; C A Hubel
Journal:  Placenta       Date:  2008-12-13       Impact factor: 3.481

7.  Placental proteomics: a shortcut to biological insight.

Authors:  J M Robinson; D D Vandré; W E Ackerman
Journal:  Placenta       Date:  2008-12-13       Impact factor: 3.481

8.  Placental pathology, first-trimester biomarkers and adverse pregnancy outcomes.

Authors:  A O Odibo; K R Patel; A Spitalnik; L Odibo; P Huettner
Journal:  J Perinatol       Date:  2014-01-16       Impact factor: 2.521

9.  A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia.

Authors:  Juan Pedro Kusanovic; Roberto Romero; Tinnakorn Chaiworapongsa; Offer Erez; Pooja Mittal; Edi Vaisbuch; Shali Mazaki-Tovi; Francesca Gotsch; Samuel S Edwin; Ricardo Gomez; Lami Yeo; Agustin Conde-Agudelo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2009-11

Review 10.  Potential markers of preeclampsia--a review.

Authors:  Simon Grill; Corinne Rusterholz; Rosanna Zanetti-Dällenbach; Sevgi Tercanli; Wolfgang Holzgreve; Sinuhe Hahn; Olav Lapaire
Journal:  Reprod Biol Endocrinol       Date:  2009-07-14       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.